Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Advanced Solid Malignancies
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 695 (planned)
- Started
- Jun 24, 2022
- Main results expected
- Feb 7, 2028
- Fully finished
- Feb 7, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of Adverse Events (AEs), and Serious Adverse Events (SAEs)
Measured over: From first dose to post-treatment follow-up (approximately three years)
Changes from baseline in laboratory findings, electrocardiograms (ECGs), and vital signs
Measured over: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
Change from baseline Eastern Cooperative Oncology Group performance status (ECOG PS)
Measured over: From last assessment prior to first dose to post-treatment follow up visit (approximately three years)
Incidence of Dose Limiting Toxicities (DLTs)
Measured over: Cycle 0 and Cycle 1 (Day 1 to Day 35)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05417594 · record last updated 2026-10-05 · checked 2026-11-09 15:47 UTC